{"filings":[{"id":103173,"accession_number":"0001640334-26-000230","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lexaria Bioscience receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency notice on Feb 4, 2026 for failing to meet $1.00 min bid price (Rule 5550(a)(2)).","Compliance period runs 180 calendar days, until August 3, 2026, to regain compliance.","To cure, closing bid price must be ≥$1.00 for at least 10 consecutive business days during period.","If not cured, company may seek second 180-day period if it meets other initial listing standards.","Failure to regain compliance could lead to delisting; company is evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103172,"accession_number":"0001640334-26-000162","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lexaria Bioscience shareholders elect all director nominees, ratify auditors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: highest vote % John Docherty (96.4%), lowest Albert Reese Jr. (73.6%).","Malone Bailey LLP ratified as auditors with 97.0% approval.","Ratification of directors' past actions passed with 90.0% approval.","8,380,389 shares (37.71% of issued capital) represented at the meeting.","Broker non-votes totaled 3,963,206 on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119407,"accession_number":"0001640334-25-002348","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lexaria raises $3.5M in registered direct offering with warrants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Issued 2,661,600 shares at $1.315/share, gross proceeds ~$3.5M.","Concurrent private placement of warrants for 2,661,600 shares at $1.19 exercise price, 5-year term.","H.C. Wainwright acted as exclusive placement agent; fees 7% cash plus 93,156 placement agent warrants at $1.6438.","Net proceeds to fund R&D, working capital, and general corporate purposes.","Offering closed on December 16, 2025; shares registered under Form S-3, warrants unregistered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135962,"accession_number":"0001640334-25-001742","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lexaria closes $4M registered direct offering of 2.67M shares at $1.50 with warrants at $1.37","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed on Sept 29, 2025: gross proceeds of $4.0M from 2,666,667 shares at $1.50 and warrants.","Warrants for 2,666,667 shares at $1.37, immediately exercisable, 5-year term from resale registration.","Placement agent H.C. Wainwright receives 7% cash fee and 93,333 warrants at $1.875 exercise price.","Net proceeds for working capital and general corporate purposes; CEO cites 2026 R&D and BD plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135961,"accession_number":"0001640334-25-001717","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Lexaria Bioscience terminates $5M equity distribution agreement with JonesTrading","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Capital on Demand Sales Agreement with JonesTrading effective September 19, 2025.","Agreement allowed up to $5M in common stock; only 14,995 shares sold for $38,236 gross proceeds.","Original agreement dated Aug 21, 2024; amended Feb 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152993,"accession_number":"0001640334-25-001030","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.0"],"status":"ready","headline":"Lexaria expands GLP-1-H24-4 trial with 5th tirzepatide arm","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added 5th study arm investigating DehydraTECH-tirzepatide capsules in GLP1-H24-4 diabetes trial.","Existing four arms increased from 20 to 24 subjects; new arm will recruit 24 subjects.","Change Order with Novotech adds ~AU$1,900,000 to approved budget.","Human research ethics committee approval for the new arm was granted Feb 24, 2025.","Study evaluates DehydraTECH delivery of cannabidiol and GLP-1 agonists in pre/Type II diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152992,"accession_number":"0001640334-25-000711","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lexaria raises $2M via registered direct offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $2M from sale of 2M shares/pre-funded warrants at $1.00 per share to one institutional investor.","No new warrants issued to investor other than pre-funded warrants; placement agent gets 70,000 warrants at $1.25.","Offering closed April 28, 2025; net proceeds for working capital and general corporate purposes.","CEO states transaction minimized dilution during uncertain market; H.C. Wainwright acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171778,"accession_number":"0001640334-25-000192","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lexaria reduces at-the-market equity facility from $20M to $5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Capital on Demand Sales Agreement with JonesTrading; maximum aggregate principal amount reduced to $5M from $20M.","Shares sold under new registration statement on Form S-3 (333-284407), effective Jan 30, 2025.","Agent commission remains 3.0% of gross sales price; customary indemnification and expense reimbursement.","Offering terminates upon sale of all Shares or termination of agreement by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171777,"accession_number":"0001640334-25-000087","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lexaria shareholders re-elect all directors; McKechnie gets 54% support, Baxter 62%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting on Jan 14, 2025: 9,761,279 shares (55.93% of outstanding) represented.","Directors elected: Bunka 89%, Docherty 98%, Baxter 62%, McKechnie 54%, Reese 90%, Christopher 98%, Bhullar 98%.","Say-on-pay frequency approved every three years with 66% of votes cast; advisory compensation passed at 97%.","Warrant exercise proposal approved by 70% of votes cast; auditor Malone Bailey LLP ratified with 98%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171776,"accession_number":"0001640334-25-000009","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lexaria Bioscience enters new exec agreement with President/CSO Docherty; base salary, 50% bonus, 15-mo severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["New agreement effective Jan 1, 2025, replaces prior 2022 pact; Docherty remains President and Chief Scientific Officer.","Base salary subject to 5% annual increases on Jan 1, 2026 and Jan 1, 2027; performance bonuses up to 50% of base.","Change of control: up to 24 months base salary plus 2% of affiliate sale value, payable within 90 days.","Severance without cause or for good reason: 15 months base salary, increasing by 1 month per additional year to max 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188776,"accession_number":"0001640334-24-001908","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.0"],"status":"ready","headline":"Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.","Aggregate costs ~AUD$5.1 million; upfront payments ~AUD$414,600 (direct) and ~AUD$347,800 (pass-through).","Lexaria AU can terminate the Project Agreement with or without cause upon 90 days' notice.","Initial start-up work already completed under a separate Start-Up Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188775,"accession_number":"0001640334-24-001541","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Lexaria Bioscience sets Jan 14, 2025 annual/special meeting; director nomination deadline Nov 25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joint Annual and Special Meeting scheduled for January 14, 2025.","Stockholder approval required for Private Placement Warrants issued in October 2024.","Director nominee submissions due by noon ET on November 25, 2024, to Vanessa Carle.","Submission address: vcarle@lexariabioscience.com; Schedule 14N required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188774,"accession_number":"0001640334-24-001537","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lexaria raises $5M via registered direct offering and private placement of warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 1,633,987 shares at $3.06/share plus 4,551,019 warrants exercisable at $3.06.","Warrants exercisable only after stockholder approval; expire 5 years from approval date.","Included cancellation of 2,917,032 outstanding warrants issued in April 2024.","Net proceeds to be used for working capital and general corporate purposes.","Placement agent H.C. Wainwright receives 7% cash fee and warrants for 57,190 shares at $3.825."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188773,"accession_number":"0001640334-24-001473","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lexaria Bioscience appoints Michael Shankman as CFO, effective Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Shankman, CPA, replaces resigned CFO Nelson Cabatuan; CEO Richard Christopher had been interim principal financial officer.","Shankman previously served as outsourced CFO via NowCFO from June 2023 to February 2024.","Compensation: base salary with inflation-adjusted annual increases; performance bonuses up to 35-50% of base salary.","Granted incentive stock option for 50,000 shares at $3.17 exercise price, vesting in three tranches through August 31, 2026.","Severance: if terminated without cause after 6 months, two months' base salary plus one additional month per year of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205245,"accession_number":"0001640334-24-001396","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Lexaria appoints Richard Christopher as CEO; Bunka transitions to Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Christopher, 54, appointed CEO effective Aug 31, 2024; he also serves as interim CFO until new CFO is hired.","Christopher receives 200,000 stock options at $3.92, base salary with 5% annual raises in 2025-26, and 50% of salary bonus target.","Outgoing CEO Bunka's letter: $8.5M raised YTD 2024, market cap ~$60M, Phase 1b hypertension study expected H1 2025.","GLP-1 R&D shows positive data; DehydraTECH-CBD outperforms in weight loss and blood sugar control in animal studies.","Bunka remains Chairman and Executive Strategic Advisor; cites need for pharma operational expertise for execution phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205244,"accession_number":"0001640334-24-001346","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lexaria Bioscience enters $20M at-the-market equity sales agreement with JonesTrading","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $20M of common stock may be sold from time to time through Agent JonesTrading as ATM offering.","Agent will receive 3.0% commission on gross sales price; Company reimburses certain expenses.","Shares sold under previously effective shelf registration statement (File No. 333-262402).","Agreement terminates upon sale of all Shares or earlier termination by either party.","No assurance any Shares will be issued; proceeds used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205243,"accession_number":"0001640334-24-001132","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Lexaria animal study interim results: DehydraTECH liraglutide and CBD show weight loss; CFO Cabatuan resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Nelson Cabatuan resigned effective July 15; becomes Chief Strategic Financial Advisor; 150k unvested options expire, vested 50k options reduced to July 2026.","In study WEIGHT-A24-1, DehydraTECH-CBD3 and DehydraTECH-liraglutide showed largest weight loss: -1.50% and -1.58% over 28 days.","DehydraTECH works with semaglutide both with and without SNAC; pure semaglutide arm performed similarly to reformulated Rybelsus.","Dosing in final four study arms (Cohort 2) began, combining DehydraTECH-semaglutide+CBD and DehydraTECH-liraglutide+CBD; results expected mid-October.","Study is exploratory; not powered for statistical significance; blood glucose and PK data pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222130,"accession_number":"0001640334-24-000708","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lexaria exercises warrants for ~$4.4M, issues new warrants with $4.75 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing investor exercises 2,917,032 warrants for ~$4.4M; gross proceeds ~$4.7M including new warrant consideration.","New warrants for 2,917,032 shares at $4.75 strike, expiring Feb 2029; $0.125/share consideration paid.","Company to file resale registration statement within 60 days for new warrant shares.","H.C. Wainwright earns 6% tail fee on proceeds and receives 102,097 warrants at $5.9375.","New warrants include 9.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222129,"accession_number":"0001640334-24-000702","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lexaria Bioscience shareholders elect all six directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with 85-99% support: Bunka, Docherty, Baxter, McKechnie, Reese Jr., Turkel.","Malone Bailey LLP ratified as auditors with 99% of votes cast.","Ratification of directors' actions passed with 97% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241647,"accession_number":"0001640334-24-000446","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["1.0"],"status":"ready","headline":"Lexaria Bioscience amends Japanese license deal; lowers minimum fees, drops exclusivity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Original exclusive perpetual license with Premier becomes non-exclusive, ending Aug 31, 2025.","Quarterly minimum fees reduced: $84,000 for May & Aug 2024, then $174,000 through Aug 2025.","Previous schedule had fees up to $332,500/quarter from Nov 2025; now capped at $174,000.","Amendment effective March 15, 2024; signed by all parties on March 21, 2024.","Parentco assumed obligations after acquiring Premier in November 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241646,"accession_number":"0001640334-24-000410","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lexaria Bioscience appoints Nelson Cabatuan as CFO effective March 14, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nelson Cabatuan, age 46, replaces temporary outsourced CFO services from NOW CFO.","Base annual salary of US$198,000 with agreed annual increases of US$12,000 for first two years.","Option grant of up to 200,000 common shares vested over three years; performance bonuses up to 35-50% of base.","Exit compensation: upon sale of affiliate, 0.5%-1.0% of gross sale value; change-of-control triggers 12-14 months base salary.","Cabatuan brings over 15 years biotech finance experience; previously SVP at Rain Oncology and VP at Rigel Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241645,"accession_number":"0001640334-24-000328","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lexaria Bioscience receives FDA clearance for Phase 1b hypertension trial HYPER-H23-1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA issued 'Study May Proceed' letter on Feb 29, 2024, for Lexaria's Investigational New Drug application.","Trial HYPER-H23-1 is a randomized, double-blind, placebo-controlled study of DehydraTECH-CBD in Stage 1 or Stage 2 hypertension.","Clinical trial commencement is contingent on Lexaria raising sufficient funding.","FDA review completion marks a key milestone for Lexaria's DehydraTECH-CBD program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241644,"accession_number":"0001640334-24-000271","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lexaria raises $3.6M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.6M from issuance of 1,558,443 shares at $2.31/share and pre-funded warrants at $2.3099.","Private placement issued unregistered warrants for up to 1,558,443 shares at $2.185 exercise price, 5-year term.","Net proceeds earmarked for R&D studies, patent/legal costs, and general working capital.","H.C. Wainwright acted as exclusive placement agent; fees equal 7% (6% for one investor) of gross proceeds plus agent warrants.","Officers and directors subject to 30-day lock-up on common stock and equivalents post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241643,"accession_number":"0001640334-24-000167","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lexaria files IND with FDA for phase 1b hypertension trial of DehydraTECH-CBD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted IND to FDA on Jan 29, 2024, for phase 1b trial HYPER-H23-1 in stage 1 or 2 hypertension.","Primary objective: evaluate safety and tolerability; secondary: blood pressure reduction and pharmacokinetics.","IND review takes minimum 30 days; trial start subject to FDA effectiveness and funding.","This marks formal regulatory scrutiny toward pharmaceutical commercial registration for DehydraTECH technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241642,"accession_number":"0001640334-24-000137","cik":1348362,"company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lexaria CEO provides 2024 outlook; GLP-1 pilot shows DehydraTECH semaglutide benefit; IND filing imminent","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Stock recovered above $1, avoiding reverse split; October capital raise on less punitive terms.","DehydraTECH semaglutide pilot (7 subjects) showed statistically higher drug proportion, faster absorption, fewer side effects vs Rybelsus.","FDA IND application for hypertension delayed ~5 months due to supplier; submission expected soon.","No debt taken in 2023 and no plan for debt in 2024; institutional holders rose to 19 with 1.8M shares.","R&D highlights: catestatin, inflammatory biomarkers, weight loss, blood glucose reduction, and nicotine study beating Zyn/On."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15365736.574881596,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}